MONTHLY IBANDRONATE REDUCES BONE LOSS IN OSTEOPENIC WOMEN WITH RHEUMATOID ARTHRITIS RECEIVING LONG-TERM GLUCOCORTICOIDS: A 48-WEEK DOUBLE-BLINDED RANDOMIZED PLACEBO-CONTROLLED INVESTIGATOR-INITIATED TRIAL

被引：0

作者：

Shin, K. ^{[1
]}

Park, S. -H. ^{[2
]}

Park, W. ^{[3
]}

Baek, H. -J. ^{[4
]}

Lee, Y. -J. ^{[5
]}

Kang, S. -W. ^{[6
]}

Choe, J. -Y. ^{[7
]}

Yoo, W. -H. ^{[8
]}

Park, Y. -B. ^{[9
]}

Song, J. -S. ^{[10
]}

Yoo, B. ^{[11
]}

Yoo, D. -H. ^{[12
]}

Song, Y. W. ^{[13
]}

机构：

[1] SMG SNU Boramae Med Ctr, Div Rheumatol, Seoul, South Korea

[2] Catholic Univ Korea, Seoul St Marys Hosp, Div Rheumatol, Seoul, South Korea

[3] Inha Univ Hosp, Div Rheumatol, Incheon, South Korea

[4] Gachon Univ, Gil Med Ctr, Div Rheumatol, Incheon, South Korea

[5] Seoul Natl Univ, Bundang Hosp, Div Rheumatol, Bundang, South Korea

[6] Chungnam Natl Univ Hosp, Div Rheumatol, Daejeon, South Korea

[7] Daegu Catholic Univ, Med Ctr, Div Rheumatol, Daegu, South Korea

[8] Chonbuk Natl Univ Hosp, Div Rheumatol, Jeonju, South Korea

[9] Yonsei Univ, Severance Hosp, Coll Med, Div Rheumatol, Seoul, South Korea

[10] Chung Ang Univ Hosp, Div Rheumatol, Seoul, South Korea

[11] Univ Ulsan, Coll Med, Asan Med Ctr, Div Rheumatol, Seoul, South Korea

[12] Hanyang Univ, Med Ctr, Div Rheumatol, Seoul, South Korea

[13] Seoul Natl Univ Hosp, Div Rheumatol, Seoul, South Korea

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷

关键词：

D O I：

10.1136/annrheumdis-2015-eular.3204

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SAT0286

引用

页码：762 / 762

页数：1

共 26 条

[21] Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial
Hakala, M.
Kroger, H.
Valleala, H.
Hienonen-Kempas, T.
Lehtonen-Veromaa, M.
Heikkinen, J.
Tuomiranta, T.
Hannonen, P.
Paimela, L.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2012, 41 (04) : 260 - 266
[22] Long-term safety and tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment:: A multicenter, randomized, double-blind, placebo-controlled, 48-week extension study
Masana, L
Mata, P
Gagné, C
Sirah, W
Cho, M
Johnson-Levonas, AO
Meehan, A
Troxell, JK
Gumbiner, B
CLINICAL THERAPEUTICS, 2005, 27 (02) : 174 - 184
[23] Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities - A randomized, double-blind, placebo-controlled trial
Greenspan, SL
Schneider, DL
McClung, MR
Miller, PD
Schnitzer, TJ
Bonin, R
Smith, E
DeLucca, P
Gormley, GJ
Melton, ME
ANNALS OF INTERNAL MEDICINE, 2002, 136 (10) : 742 - 746
[24] Long-Term Efficacy and Augmentation Assessment of a Dopamine Agonist (Pramipexole) Compared with an Alpha-2-Delta Ligand (Pregabalin) in Restless Legs Syndrome: Results of a Randomized, Double-Blinded, Placebo-Controlled Trial
Garcia-Borreguero, Diego
Chen, Crystal
Allen, Richard
Winkelman, John
Dubrava, Sarah
Miceli, Jeffrey
Knapp, Lloyd
NEUROLOGY, 2012, 79 (11) : E87 - E87
[25] Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial
Bingham, Clifton O., III
Mendelsohn, Alan M.
Kim, Lilianne
Xu, Zhenhua
Leu, Jocelyn
Han, Chenglong
Lo, Kim Hung
Westhovens, Rene
Weinblatt, Michael E.
ARTHRITIS CARE & RESEARCH, 2015, 67 (12) : 1627 - 1636
[26] Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: A three-year, double-blind, placebo-controlled, randomized clinical trial
Greenspan, SL
Resnick, NM
Parker, RA
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (05): : 2762 - 2767

← 1 2 3 →